On May 5, 2026, BiomX Inc. reported a significant shift in its business focus from phage therapy to defense and security technologies following the discontinuation of its prior product development and insolvency proceedings in Israel. This includes acquiring interests in two Israeli companies, DFSL and Zorronet, to enhance capabilities in detection systems and AI-powered security solutions, reflecting a new direction in their corporate strategy.